# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for o...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...
Bristol Myers Squibb (NYSE:BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-T...
Jefferies analyst Akash Tewari maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $49 to...
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...